Floatz logo

Donanemab

Lewy Body Disease

Eli Lilly and Companymonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

36 Active assets in the Lewy Body Disease cohort.

Asset / SponsorPhaseRating
Namenda
Zealand University Hospital
Phase 4BBB
6H-BENZOFURO(3A,3,2-EF)(2)BENZAZEPIN-6-OL, 4A,5,9,10,11,12-HEXAHYDRO-3-METHOXY-11-METHYL-, (4AS,6R,8AS)
Virginia Commonwealth University
Phase 4BB
INTEPIRDINE
Axovant Sciences Ltd.
Phase 2/3BB
Sitagliptin
Mayo Clinic
Phase 4BB
Armodafinil
NYU Langone Health
Phase 4BB

View all 50 →

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
APP-related brain and vascular amyloidosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →